Allergy Therapeutics Plc (LON:AGY) is the topic of conversation with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary talks through the preliminary results for the year
Allergy Therapeutics plc LON:AGY the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces preliminary results for the year ended 30 June 2016. Highlights — 19% increase in revenue at constant
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will issue its preliminary results for the twelve-month period ended 30 June 2016 on Monday 26 September
Panmure Gordon Analyst talks about Allergy Therapeutics PLC LON:AGY this morning “Allergy Therapeutics has announced a trading update for the year ended 30 June 2016. Reported revenues are expected to
Commenting on the positive trading update, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY said: Our strong sales growth of 19%* at constant rates and further gain in market share
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics LON:AGY, said: “This data further reinforces the benefits of Acarovac Plus(TM) in the perennial allergy vaccine market. Using maintenance injections six
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has told DirectorsTalk today that data was presented in a Satellite Symposium entitled: “Adjuvants in Allergy: elevating
Zeus Capital Dr Gary Waanders talks to DirectorsTalk about the positive headline results from Allergy Therapeutics Plc (LON:AGY). Gary explains how the vaccine is supposed to benefit patients, what the
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. It’s lead product, Pollinex Quattro is available in Europe only on a ‘Named Patient’
Panmure Gordon Analyst Dr Mike Mitchell said this morning “Allergy Therapeutics has announced top-line results from its PQBirch204 Phase II study. Primary endpoint has been met and the results have
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
